BTEK:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (GBP)

ETF | Others |

Last Closing

USD 4.824

Change

-0.04 (-0.72)%

Market Cap

USD 0.49B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-16 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

+1.75 (+0.98%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+8.60 (+0.99%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.16 (+0.92%)

USD 617.54B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.02 (+0.17%)

USD 617.54B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

+4.75 (+0.24%)

USD 348.03B
0QZK:LSE Coca-Cola Co.

-0.80 (-1.30%)

USD 266.08B
0QZO:LSE 0QZO

+0.70 (+0.62%)

USD 258.54B

ETFs Containing BTEK:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.55% 22% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.55% 21% F 33% F
Trailing 12 Months  
Capital Gain -1.45% 25% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.45% 23% F 41% F
Trailing 5 Years  
Capital Gain 35.75% 59% D- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.75% 56% F 65% D
Average Annual (5 Year Horizon)  
Capital Gain 108.85% 94% A 95% A
Dividend Return 108.85% 93% A 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 1,225.62% 5% F 4% F
Risk Adjusted Return 8.88% 37% F 50% F
Market Capitalization 0.49B 70% C- 60% D-

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.